F&C Asset Management’s Biogen BIIB Stock Holding History

F&C Asset Management’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q1	$43.2M	Sell	141,205 -20,800	-13%	-$6.6M	0.55%	41
2013 Q4	$45.3M	Buy	162,005 +8,085	+5%	+$2.09M	0.55%	38
2013 Q3	$37.1M	Buy	153,920 +233	+0.2%	+$52.1K	0.48%	40
2013 Q2	$33.1M	Buy	+153,687	New	+$32.8M	0.45%	41

Other funds holding BIIB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

F&C Asset Management's BIIB Position: Q1 2014 in Review

F&C Asset Management reduced its Biogen (BIIB) stake by 13% in Q1 2014, selling an estimated $6.6M and leaving 141,205 shares worth $43.2M. The position accounts for 0.55% of the portfolio, ranked #41.

F&C Asset Management first reported a position in BIIB in Q2 2013 and has held it in 4 quarters since. The position peaked at $45.3M in Q4 2013. 776 funds tracked by Wall St. Rank hold BIIB as of Q1 2014.

F&C Asset Management held 141,205 shares of Biogen worth $43.2M as of Q1 2014.
F&C Asset Management sold 20,800 Biogen shares in Q1 2014, an estimated $6.6M.
Biogen made up 0.55% of F&C Asset Management's portfolio in Q1 2014, its #41 holding.
F&C Asset Management first reported a position in Biogen in Q2 2013 and has held it in 4 quarters since.
F&C Asset Management's Biogen position peaked at $45.3M in Q4 2013.
776 funds tracked by Wall St. Rank held Biogen as of Q1 2014.

Based on F&C Asset Management's 13F filing for Q1 2014, filed 14 May 2014.